Dutch Biotech Moves Hepatitis B Vaccine For Huge China Market
This article was originally published in PharmAsia News
Executive Summary
Crucell, a biopharma company based in The Netherlands, has applied for registration and quality control of its hepatitis B vaccine in China where it believes the market to be $100 million. The Hepavax-Gene is the world's third-best selling vaccine for the disease, accounting for 600 million doses worth of sales in the past 12 years. In China, the Dutch biotech is aiming for the country's high-end sector dominated by young adults. One advantage in China is the vaccine contains no thiomersal, which already is being phased out for treatment of children in other countries. (Click here for more